Simulations Plus, Inc.
HealthcareNASDAQ:SLP · NASDAQ Global Select
-$0.17 today
Vol 0.16M · Avg 0.33M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-51.9%
avg 8.5%
ROIC
-52.6%
avg 6.2%
ROA
-49.1%
avg 5.8%
Analysis
ROA is currently the strongest return metric at -49.1% versus its period average of 5.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Shawn O'Connor | Chief Executive Officer | $529,122.00 | — | 66 | $50,000.00 | 0.25% |
William Frederick | CFO, Executive VP & Corporate Secretary | $360,053.00 | — | 62 | $32,500.00 | 0.16% |
John Anthony DiBella | Chief Revenue Officer | $358,022.00 | — | 46 | $87,140.00 | 0.43% |
Steven Chang | Global Head of Strategic Alliances | $351,326.00 | — | 58 | $0.00 | <0.01% |
Jill Fiedler-Kelly | President of Services Solutions | $334,128.00 | — | 56 | $78,817.00 | 0.39% |
Josh Fohey | Chief Operating Officer | $270,973.00 | — | 43 | — | — |
Jennifer Presnell | Accounting Manager | — | — | — | — | — |
Bud Nelson | Vice President of Corporate Counsel & Personal Data Protection Officer | — | — | — | — | — |
Christina Hendrickson | Senior Director of Corporate Marketing | — | — | — | — | — |
Viera Lukacova | Chief Science Officer | — | — | 52 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
12
$1.26M
Net Sentiment
$1.26M
Net selling
Most Active
WOLTOSZ WALTER S
5 transactions
1–10 of 12
Analysis
Insiders reported 0 buys worth $0.00 and 12 sells worth $1.26M over the last 12 months. That adds up to net selling of $1.26M. WOLTOSZ WALTER S was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +6.6% | +13.6% (15yr)1 analysts |
| Revenue | N/A | N/A | +24.7% | +13.2% (15yr)1 analysts |
| Net Income | N/A | N/A | +8.3% | +15.0% (15yr)1 analysts |
| EBIT | N/A | N/A | +17.5% | +8.4% (15yr)1 analysts |
Analysis
Recent growth has been strongest in Revenue at +24.7% over three years. Forward estimates point to Net Income at +15.0% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Agilon Health, Inc.
NYSE:AGL
$1.88B
Alto Neuroscience, Inc.
NYSE:ANRO
$753.47M
National Research Corporation
NASDAQ:NRC
$423.46M
SOPHiA GENETICS S.A.
NASDAQ:SOPH
$349.74M
Cellectis S.A.
NASDAQ:CLLS
$310.29M
AC Immune S.A.
NASDAQ:ACIU
$235.10M
Korro Bio, Inc.
NASDAQ:KRRO
$115.56M
OptimizeRx Corporation
NASDAQ:OPRX
$98.14M
Definitive Healthcare Corp.
NASDAQ:DH
$88.59M
Nakamoto Inc.
NASDAQ:NAKA
$75.18M
Who manages SLP?
Simulations Plus, Inc. (SLP) lists 10 active executives. The top listed executive is Steven Chang, Global Head of Strategic Alliances.
Are SLP insiders buying or selling?
Recent insider activity shows net selling of $14.66M.
Explore More
Continue the stock analysis
Jump to another research area for this company.